WeVote
Log In

Bill

Bill

HB 1214

Health insurance; cost-sharing payments for insulin and diabetes equipment and supplies, limit.

2026 Regular Session Introduced by Elizabeth Bennett-Parker and 5 co-sponsors

Virginia bill limits health insurance cost-sharing for insulin and diabetes supplies to improve patient affordability and medication access.

Approved by Governor-Chapter 752 (effective 7/1/2026)
0
WeVote Research Nonpartisan
Bill Summary · HB 1214

Legislative bill overview

HB 1214 limits cost-sharing payments (copays, coinsurance, deductibles) that health insurance plans can require for insulin and diabetes-related equipment and supplies in Virginia. The bill aims to reduce out-of-pocket expenses for diabetic patients by capping what insurers can charge for these essential medications and medical devices.

Why is this important

Diabetes affects over 800,000 Virginians, and insulin costs have risen dramatically, forcing many patients to ration doses or skip treatments due to affordability. By reducing cost-sharing barriers, the bill could improve medication adherence and prevent serious health complications, though it may affect insurance premium costs and plan design flexibility.

Potential points of contention

  • Insurance cost impact: Insurers may argue that capping cost-sharing increases their claims expenses, potentially raising premiums for all enrollees or reducing plan offerings
  • Definition specificity: The bill's language on what qualifies as "diabetes equipment and supplies" may be unclear, creating disputes over coverage eligibility (e.g., continuous glucose monitors vs. test strips)
  • Market competitiveness: Stricter cost-sharing limits could disadvantage smaller insurers or reduce plan options in Virginia's health insurance marketplace, particularly for employer-sponsored plans

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.